Literature DB >> 8525376

Crystal structure of the V alpha domain of a T cell antigen receptor.

B A Fields1, B Ober, E L Malchiodi, M I Lebedeva, B C Braden, X Ysern, J K Kim, X Shao, E S Ward, R A Mariuzza.   

Abstract

The crystal structure of the V alpha domain of a T cell antigen receptor (TCR) was determined at a resolution of 2.2 angstroms. This structure represents an immunoglobulin topology set different from those previously described. A switch in a polypeptide strand from one beta sheet to the other enables a pair of V alpha homodimers to pack together to form a tetramer, such that the homodimers are parallel to each other and all hypervariable loops face in one direction. On the basis of the observed mode of V alpha association, a model of an (alpha beta)2 TCR tetramer can be positioned relative to the major histocompatibility complex class II (alpha beta)2 tetramer with the third hypervariable loop of V alpha over the amino-terminal portion of the antigenic peptide and the corresponding loop of V beta over its carboxyl-terminal residues. TCR dimerization that is mediated by the alpha chain may contribute to the coupling of antigen recognition to signal transduction during T cell activation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8525376     DOI: 10.1126/science.270.5243.1821

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  27 in total

1.  Modeling the interactions of a peptide-major histocompatibility class I ligand with its receptors. II. Cross-reaction between a monoclonal antibody and two alpha beta T cell receptors.

Authors:  D Rognan; J Engberg; A Stryhn; P S Andersen; S Buus
Journal:  J Comput Aided Mol Des       Date:  2000-01       Impact factor: 3.686

2.  Modeling the interactions of a peptide-major histocompatibility class I ligand with its receptors. I. Recognition by two alpha beta T cell receptors.

Authors:  D Rognan; A Stryhn; L Fugger; S Lyngbaek; J Engberg; P S Andersen; S Buus
Journal:  J Comput Aided Mol Des       Date:  2000-01       Impact factor: 3.686

3.  A relation between the principal axes of inertia and ligand binding.

Authors:  J Foote; A Raman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

4.  Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis.

Authors:  B Murphy; C C Magee; S I Alexander; A M Waaga; H W Snoeck; J P Vella; C B Carpenter; M H Sayegh
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

5.  The immune function of MHC class II molecules mutated in the putative superdimer interface.

Authors:  John D Hayball; Richard A Lake
Journal:  Mol Cell Biochem       Date:  2005-05       Impact factor: 3.396

6.  Multivalent structure of an alphabetaT cell receptor.

Authors:  G Fernández-Miguel; B Alarcón; A Iglesias; H Bluethmann; M Alvarez-Mon; E Sanz; A de la Hera
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

7.  Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex.

Authors:  A Stryhn; P S Andersen; L O Pedersen; A Svejgaard; A Holm; C J Thorpe; L Fugger; S Buus; J Engberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

8.  Rejection of cardiac allografts by T cells expressing a restricted repertoire of T-cell receptor V beta genes.

Authors:  H Shirwan; L Barwari; D V Cramer
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

9.  Cloning, expression, and crystallization of the V delta domain of a human gamma delta T-cell receptor.

Authors:  M I Lebedeva; B A Fields; H Spits; G Panchamoorthy; M B Brenner; R A Mariuzza
Journal:  Protein Sci       Date:  1996-12       Impact factor: 6.725

10.  Conserved T-cell receptor class II major histocompatibility complex contact detected in a T-lymphocyte population.

Authors:  M Feng; D Chou; Y Liaw; M Lai
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.